Breaking News, Collaborations & Alliances

Tetra Bio-Pharma, Cellvera to Co-Develop Potential Oral Covid Treatment

The parties hypothesize a combination product of Favipiravir and ARDS-003 has the potential to allow rapid virus clearance and longer-term patient benefits.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug.      As a monotherapy, compared to placebo, ARDS-003 dose-dependently reduced signs of morbidity and mortality, including respiratory distress following SARS-CoV-2 infection in the humanized ACE2 mouse model. ARDS-003 also outperformed an antiviral drug in reducing multipl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters